An observational study in Efficacy and Safety of Dalbavancin, In Subjects Who Received SAT with DAL and For Acute or Chronic Infections Between July 2019 and December 2024, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2025-03-28.
Sponsored by Hospices Civils de Lyon · Observational
Dalbavancin (DAL) is a semi-synthetic antibiotic that belongs to the lipoglycopeptide family and is structurally derived from teicoplanin, respect of which it has two structural differences that enhance its anti-staphylococcal binding affinity and extend its half-life to between 149 and 250 hours. It achieves adequate tissue penetration in the skin, bones, joints, lung tissues, and peritoneal space, maintaining concentrations above the MIC for susceptible Gram-positive pathogen.
DAL is a bactericidal antimicrobial agent that binds the C-terminal D-alanyl-D-alanine on the bacterial cell wall, blocking trans-glycosylation and transpeptidation processes essential for cell wall synthesis. It seems also to be able to enhance neutrophil antibacterial activity improving PMNs' intracellular killing of MRSA. It has also a good antibiofilm activity, alone or in combination with other molecules. Like other glycopeptide molecules, DAL shares a similar spectrum of activity, with demonstrated in vitro activity against various Gram-positive bacteria, including Staphylococcus spp, Streptococcus spp and Enterococcus (faecium, and faecalis). Resistance to DAL is possible in these gram-positives bacteria, given to presence of enzymes that produce low-affinity binding precursors for the antibiotic's binding site. DAL is capable to overcome Van-B mechanism of resistance, but it results not active in producing Van-A strains.
The study objectives was to evaluate efficacy and safety of DAL treatment.
44 studies on the registry are indexed under Persistent Infection; 5 are open to participants now.
This study's planned enrollment of 33 is below the median of 150 across 15 observational studies indexed under Persistent Infection.
Browse Persistent Infection studies →Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients managed for gram-positive infection between July 2019 and December 2024 in the MIT department.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The study population included subjects aged ≥ 18 years who received SAT with DAL for acute or chronic infections (defined as a long-standing infection due to a previously uneradicated pathogen, following unsuccessful antibiotic or surgical treatments) between July 2019 and December 2024. Subjects younger than 18 years and those who received DAL not for SAT purposes were excluded.
Other: Determine patient demographic and clinical characteristics at baseline
Description of demographic data (sex, age), comorbidities (Charlson scores), septic history, and medical management (antibiotic therapy)
efficacy of DAL treatment, measured as the proportion of stable infection
Time frame: Outcome will be measure at 1 year. For patients lost of follow-up or followed-up less than a year, the date of last visit will be used for survival curve analysis .
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.